Literature DB >> 17706158

Recognizing the toxicity of "nontoxic" drugs employed in the management of malignant disease.

Maurie Markman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17706158     DOI： 10.1007/s11912-007-0041-0

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


× No keyword cloud information.
  16 in total

Review 1.  Cardiotoxicity of cancer therapy.

Authors:  K A Tolba; E N Deliargyris
Journal:  Cancer Invest       Date:  1999       Impact factor: 2.176

2.  Is it all over for erythropoietin?

Authors:  Adrian Burton
Journal:  Lancet Oncol       Date:  2007-04       Impact factor: 41.316

3.  What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?

Authors:  Ernest S Han; Bradley J Monk
Journal:  Gynecol Oncol       Date:  2007-04       Impact factor: 5.482

Review 4.  Osteonecrosis of the jaw associated with bisphosphonate use: Presentation of seven cases and literature review.

Authors:  Melissa Mortensen; William Lawson; Andre Montazem
Journal:  Laryngoscope       Date:  2007-01       Impact factor: 3.325

5.  Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer.

Authors:  Michael J Hassett; A James O'Malley; Juliana R Pakes; Joseph P Newhouse; Craig C Earle
Journal:  J Natl Cancer Inst       Date:  2006-08-16       Impact factor: 13.506

6.  Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience.

Authors:  Valentina Guarneri; Daniel J Lenihan; Vicente Valero; Jean-Bernard Durand; Kristine Broglio; Kenneth R Hess; Laura Boehnke Michaud; Ana M Gonzalez-Angulo; Gabriel N Hortobagyi; Francisco J Esteva
Journal:  J Clin Oncol       Date:  2006-08-14       Impact factor: 44.544

Review 7.  Cancer patient survival and erythropoietin.

Authors:  John A Glaspy
Journal:  J Natl Compr Canc Netw       Date:  2005-11       Impact factor: 11.908

8.  Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.

Authors:  James R Wright; Yee C Ung; Jim A Julian; Kathleen I Pritchard; Timothy J Whelan; Column Smith; Barbara Szechtman; Wilson Roa; Liam Mulroy; Leona Rudinskas; Bruno Gagnon; Gord S Okawara; Mark N Levine
Journal:  J Clin Oncol       Date:  2007-02-20       Impact factor: 44.544

9.  Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study.

Authors:  Sabine Tejpar; Hubert Piessevaux; Kathleen Claes; Patricia Piront; Joost G J Hoenderop; Chris Verslype; Eric Van Cutsem
Journal:  Lancet Oncol       Date:  2007-05       Impact factor: 41.316

10.  Risk of endometrial cancer after tamoxifen treatment of breast cancer.

Authors:  F E van Leeuwen; J Benraadt; J W Coebergh; L A Kiemeney; C H Gimbrère; R Otter; L J Schouten; R A Damhuis; M Bontenbal; F W Diepenhorst
Journal:  Lancet       Date:  1994-02-19       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.